LY-CoV555, a Rapidly Isolated Potent Neutralizing Antibody, Provides Protection in a Non-human Primate Model of SARS-CoV-2 Infection

One Sentence Summary: LY-CoV555, an anti-spike antibody derived from a convalescent COVID-19 patient, potently neutralizes SARS-CoV-2 and protects the upper and lower airways of non-human primates against SARS-CoV-2 infection.

Citing Articles

Climate change and infectious disease: A prologue on multidisciplinary cooperation and predictive analytics.

Yeh K, Parekh F, Mombo I, Leimer J, Hewson R, Olinger G Front Public Health. 2023; 11:1018293.

PMID: 36741948 PMC: 9895942. DOI: 10.3389/fpubh.2023.1018293.

Heterogeneity in the spontaneous induction of the promoter of the ColE9 operon in Escherichia coli.

Bano S, Vankemmelbeke M, Penfold C, Tunio S, James R Arch Microbiol. 2022; 204(10):628.

PMID: 36114880 DOI: 10.1007/s00203-022-03242-9.

Structural and energetic profiling of SARS-CoV-2 receptor binding domain antibody recognition and the impact of circulating variants.

Yin R, Guest J, Taherzadeh G, Gowthaman R, Mittra I, Quackenbush J PLoS Comput Biol. 2021; 17(9):e1009380.

PMID: 34491988 PMC: 8448325. DOI: 10.1371/journal.pcbi.1009380.

Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern.

Falcone M, Tiseo G, Valoriani B, Barbieri C, Occhineri S, Mazzetti P Infect Dis Ther. 2021; 10(4):2479-2488.

PMID: 34435337 PMC: 8386337. DOI: 10.1007/s40121-021-00525-4.

The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody.

Chan C, Seah S, Chye D, Massey S, Torres M, Lim A PLoS One. 2021; 16(6):e0253487.

PMID: 34161386 PMC: 8221499. DOI: 10.1371/journal.pone.0253487.